Raiffeisen Bank International AG Has $1.57 Million Stock Holdings in BioNTech SE Sponsored ADR $BNTX

Raiffeisen Bank International AG boosted its position in shares of BioNTech SE Sponsored ADR (NASDAQ:BNTX) by 52.4% in the third quarter, Holdings Channel.com reports. The firm owned 16,000 shares of the company’s stock after acquiring an additional 5,500 shares during the period. Raiffeisen Bank International AG’s holdings in BioNTech were worth $1,570,000 as of its most recent SEC filing.

Other hedge funds also recently made changes to their positions in the company. BNP Paribas Financial Markets raised its position in BioNTech by 6.7% during the second quarter. BNP Paribas Financial Markets now owns 1,275,475 shares of the company’s stock worth $135,800,000 after acquiring an additional 80,005 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in shares of BioNTech by 58.8% in the 2nd quarter. Bank of New York Mellon Corp now owns 1,108,719 shares of the company’s stock valued at $118,045,000 after purchasing an additional 410,351 shares during the period. Dodge & Cox acquired a new stake in BioNTech in the 2nd quarter valued at about $93,421,000. Franklin Resources Inc. grew its holdings in BioNTech by 76.8% during the second quarter. Franklin Resources Inc. now owns 751,998 shares of the company’s stock worth $80,065,000 after purchasing an additional 326,556 shares during the period. Finally, Invesco Ltd. grew its holdings in BioNTech by 5.6% during the second quarter. Invesco Ltd. now owns 681,100 shares of the company’s stock worth $72,517,000 after purchasing an additional 35,958 shares during the period. 15.52% of the stock is owned by institutional investors.

BioNTech Stock Down 0.3%

BNTX stock opened at $110.14 on Friday. BioNTech SE Sponsored ADR has a fifty-two week low of $81.20 and a fifty-two week high of $124.00. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.12 and a quick ratio of 7.02. The stock has a market capitalization of $24.80 billion, a price-to-earnings ratio of -41.88 and a beta of 1.49. The business’s fifty day moving average price is $104.18 and its two-hundred day moving average price is $103.50.

Wall Street Analyst Weigh In

Several research firms have issued reports on BNTX. TD Cowen restated a “hold” rating on shares of BioNTech in a research note on Monday, November 3rd. The Goldman Sachs Group upgraded BioNTech from a “neutral” rating to a “buy” rating and increased their price target for the company from $115.00 to $142.00 in a research note on Friday, January 16th. Morgan Stanley reaffirmed an “overweight” rating and set a $134.00 price objective on shares of BioNTech in a research report on Monday, November 3rd. Weiss Ratings reiterated a “sell (d-)” rating on shares of BioNTech in a report on Friday, January 9th. Finally, HC Wainwright restated a “buy” rating and set a $140.00 target price on shares of BioNTech in a research note on Thursday, December 11th. Eleven investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $140.10.

About BioNTech

BioNTech SE (NASDAQ: BNTX) is a Germany-based biotechnology company that develops next-generation immunotherapies and vaccines, with a primary focus on messenger RNA (mRNA) technology. Founded in 2008 and headquartered in Mainz, BioNTech advances a platform approach to design and manufacture therapeutics across oncology, infectious diseases and other high unmet-need areas. The company is publicly traded on the NASDAQ exchange and became widely known for its rapid development and global deployment of an mRNA-based COVID-19 vaccine in collaboration with Pfizer.

BioNTech’s core activities include discovery research, clinical development and manufacturing of mRNA-based medicines, personalized cancer immunotherapies, engineered cell therapies, and antibody- and protein-based therapeutics.